

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: AOKI, et al.)	Examiner: Anish Gupta (parent appl.)
)	
Serial Number: 10/726,904)	Art Unit: 1653 (parent appl.)
)	
Filed: December 2, 2003)	Confirmation No.
)	
For: USE OF NEUROTOXIC)	
COMPONENT OF A BOTULINUM)	
TOXIN FOR TREATING VARIOUS)	
DISORDERS AND CONDITIONS AND)	
ASSOCIATED PAIN)	Irvine, California


INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the patent application entitled USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING VARIOUS DISORDERS AND CONDITIONS AND ASSOCIATED PAIN, filed herewith one copy of a documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. These documents were disclosed in a European Search Report in the foreign counterpart of the above-identified application and the European Search Report was received less than three (3)




months ago. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: January 19, 2004


Stephen Donovan
Registration Number 33,433

Please direct all inquiries and correspondence to:

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534


CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date, January 19, 2004, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV193721266US addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date: January 19, 2004

Susan Bartholomew

Name of person mailing paper


Signature of person mailing paper

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 16952 CON1 CIP3	SERIAL NO.: 10/726,904
APPLICANT: Aoki et al.	TITLE: USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING VARIOUS DISORDERS AND CONDITIONS AND ASSOCIATED PAIN
FILING DATE: December 2, 2003	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicabl)
	AA	5,696,077	12/9/97	Johnson, et al.			
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	WO 93/05800	01/04/93	PCT			
	BB	WO 94/00481	06/01/94	PCT			
	BC	WO 95/30431	16/11/95	PCT			

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Hensen, Nancy, "Deadly toxin calms excited muscles" <i>New Scientist, New Science Publications</i> , London, GB, No. 1746, 8 December 1990, pg. 24
	CB	Schantz, E.J., et al., "Properties and use of Botulinum Toxin and other microbial neurotoxins in medicine", <i>Microbiological Reviews</i> , Mar 1992, p. 80-99, Vol. 56., No. 1
	CC	
	CD	
	CE	
	CF	
	CG	
	CH	
	CI	

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.